review quotes glp-1 A new generation of obesity medications are currently being reviewed by the A monthly GLP-1 dose could

Reported benefits (per available research): Studied for restoring more youthful pulsatile GH and IGF-1 secretion in older adults, based on a small 1997 randomized, placebo-controlled human trial of a closely related GHRH(1-29) analog published in the Journal of Clinical Endocrinology & Metabolism May support gains in lean body mass in men specifically: that same 16-week trial found a statistically significant increase in lean body mass in men but not in women, alongside a significant increase in skin thickness (a marker of dermal collagen) in both sexes Proposed to support broader recovery and body-composition goals tied to growth-hormone-axis activity, though sermorelin-specific modern adult trial data remains thin, and much of the anti-aging and muscle-building framing used in commercial marketing outpaces the current clinical evidence base Known risks and side effects: Injection-site reactions (pain, swelling, or redness) are the most commonly reported adverse event associated with sermorelin therapy in manufacturer drug-labeling data Headache, flushing, dizziness, difficulty swallowing, hyperactivity, drowsiness, and hives have also been reported less commonly per that same labeling data

Data availability This project has generated both simulated and experimental, quantitative, de-identified data on the regional deposition of aerosolized nasal medication in the form of nasal spray droplets in the sinonasal passages

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits (review)

GLP-1 medicationsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro)are administered subcutaneously, meaning they are injected into the fatty tissue just beneath the skin rather than into muscle

Inconsistency between overall and subgroup analyses